EGFR and non-small cell lung carcinoma: Gefitinib is a selective tyrosine kinase receptor inhibitor targeted at epidermal growth factor receptor (EGFR) alterations and has been approved in the treatment of patients with non-small cell lung cancer (44), and in vitro research found that it had synergistic effects with cisplatin (45).